Medical - Healthcare Information Services
Compare Stocks
5 / 10Stock Comparison
PGNY vs HIMS vs LFST vs GDRX vs CVS
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Equipment & Services
Medical - Care Facilities
Medical - Healthcare Information Services
Medical - Healthcare Plans
PGNY vs HIMS vs LFST vs GDRX vs CVS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Healthcare Information Services | Medical - Equipment & Services | Medical - Care Facilities | Medical - Healthcare Information Services | Medical - Healthcare Plans |
| Market Cap | $1.57B | $6.63B | $3.43B | $973M | $111.40B |
| Revenue (TTM) | $1.29B | $2.35B | $1.49B | $788M | $407.90B |
| Net Income (TTM) | $68M | $128M | $23M | $29M | $2.93B |
| Gross Margin | 24.1% | 69.7% | 21.7% | 81.0% | 13.9% |
| Operating Margin | 7.5% | 4.6% | 3.0% | 12.4% | 1.5% |
| Forward P/E | 16.4x | 51.5x | 121.1x | 9.0x | 12.2x |
| Total Debt | $24M | $1.12B | $194M | $60M | $93.59B |
| Cash & Equiv. | $112M | $229M | $249M | $262M | $8.51B |
PGNY vs HIMS vs LFST vs GDRX vs CVS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 21 | May 26 | Return |
|---|---|---|---|
| Progyny, Inc. (PGNY) | 100 | 32.5 | -67.5% |
| Hims & Hers Health,… (HIMS) | 100 | 235.7 | +135.7% |
| LifeStance Health G… (LFST) | 100 | 31.8 | -68.2% |
| GoodRx Holdings, In… (GDRX) | 100 | 7.9 | -92.1% |
| CVS Health Corporat… (CVS) | 100 | 104.6 | +4.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PGNY vs HIMS vs LFST vs GDRX vs CVS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
PGNY ranks third and is worth considering specifically for sleep-well-at-night and defensive.
- Lower volatility, beta 0.71, Low D/E 4.7%, current ratio 2.73x
- Beta 0.71, current ratio 2.73x
- 9.0% ROA vs LFST's 1.1%, ROIC 18.1% vs 1.2%
HIMS has the current edge in this matchup, primarily because of its strength in long-term compounding.
- 161.9% 10Y total return vs CVS's 3.5%
- 59.0% revenue growth vs GDRX's 0.6%
- 5.5% margin vs CVS's 0.7%
LFST is the clearest fit if your priority is growth exposure.
- Rev growth 13.9%, EPS growth 113.3%, 3Y rev CAGR 18.3%
- +60.6% vs HIMS's -51.0%
GDRX is the clearest fit if your priority is value.
- Lower P/E (9.0x vs 12.2x)
CVS is the #2 pick in this set and the best alternative if income & stability is your priority.
- Dividend streak 0 yrs, beta 0.05, yield 3.1%
- Beta 0.05 vs HIMS's 2.40, lower leverage
- 3.1% yield; the other 4 pay no meaningful dividend
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 59.0% revenue growth vs GDRX's 0.6% | |
| Value | Lower P/E (9.0x vs 12.2x) | |
| Quality / Margins | 5.5% margin vs CVS's 0.7% | |
| Stability / Safety | Beta 0.05 vs HIMS's 2.40, lower leverage | |
| Dividends | 3.1% yield; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +60.6% vs HIMS's -51.0% | |
| Efficiency (ROA) | 9.0% ROA vs LFST's 1.1%, ROIC 18.1% vs 1.2% |
PGNY vs HIMS vs LFST vs GDRX vs CVS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
PGNY vs HIMS vs LFST vs GDRX vs CVS — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
GDRX leads in 3 of 6 categories
PGNY leads 1 • HIMS leads 1 • LFST leads 0 • CVS leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
GDRX leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CVS is the larger business by revenue, generating $407.9B annually — 517.7x GDRX's $788M. Profitability is closely matched — net margins range from 5.5% (HIMS) to 0.7% (CVS). On growth, HIMS holds the edge at +28.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1.3B | $2.3B | $1.5B | $788M | $407.9B |
| EBITDAEarnings before interest/tax | $100M | $164M | $100M | $184M | $10.5B |
| Net IncomeAfter-tax profit | $68M | $128M | $23M | $29M | $2.9B |
| Free Cash FlowCash after capex | $181M | $73M | $179M | $132M | $7.4B |
| Gross MarginGross profit ÷ Revenue | +24.1% | +69.7% | +21.7% | +81.0% | +13.9% |
| Operating MarginEBIT ÷ Revenue | +7.5% | +4.6% | +3.0% | +12.4% | +1.5% |
| Net MarginNet income ÷ Revenue | +5.2% | +5.5% | +1.6% | +3.7% | +0.7% |
| FCF MarginFCF ÷ Revenue | +14.0% | +3.1% | +12.0% | +16.7% | +1.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +1.4% | +28.4% | +21.2% | -4.4% | +6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +70.6% | -27.3% | — | -1.3% | +63.1% |
Valuation Metrics
GDRX leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 29.5x trailing earnings, PGNY trades at a 93% valuation discount to LFST's 442.5x P/E. On an enterprise value basis, GDRX's 4.0x EV/EBITDA is more attractive than HIMS's 42.7x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1.6B | $6.6B | $3.4B | $973M | $111.4B |
| Enterprise ValueMkt cap + debt − cash | $1.5B | $7.5B | $3.4B | $771M | $196.5B |
| Trailing P/EPrice ÷ TTM EPS | 29.48x | 50.32x | 442.50x | 33.29x | 62.81x |
| Forward P/EPrice ÷ next-FY EPS est. | 16.39x | 51.51x | 121.07x | 8.98x | 12.19x |
| PEG RatioP/E ÷ EPS growth rate | 4.40x | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 16.41x | 42.68x | 41.98x | 4.01x | 13.11x |
| Price / SalesMarket cap ÷ Revenue | 1.22x | 2.82x | 2.41x | 1.22x | 0.28x |
| Price / BookPrice ÷ Book value/share | 3.32x | 12.25x | 2.28x | 1.65x | 1.47x |
| Price / FCFMarket cap ÷ FCF | 8.18x | 89.61x | 31.20x | 5.92x | 14.27x |
Profitability & Efficiency
PGNY leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
HIMS delivers a 23.7% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $2 for LFST. PGNY carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to HIMS's 2.07x. On the Piotroski fundamental quality scale (0–9), LFST scores 7/9 vs HIMS's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +13.3% | +23.7% | +1.6% | +4.8% | +3.9% |
| ROA (TTM)Return on assets | +9.0% | +6.0% | +1.1% | +1.9% | +1.1% |
| ROICReturn on invested capital | +18.1% | +10.7% | +1.2% | +13.0% | +5.0% |
| ROCEReturn on capital employed | +17.4% | +10.9% | +1.3% | +8.8% | +6.1% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 | 7 | 6 | 5 |
| Debt / EquityFinancial leverage | 0.05x | 2.07x | 0.13x | 0.10x | 1.24x |
| Net DebtTotal debt minus cash | -$88M | $892M | -$55M | -$202M | $85.1B |
| Cash & Equiv.Liquid assets | $112M | $229M | $249M | $262M | $8.5B |
| Total DebtShort + long-term debt | $24M | $1.1B | $194M | $60M | $93.6B |
| Interest CoverageEBIT ÷ Interest expense | — | — | 3.30x | 3.61x | 2.11x |
Total Returns (Dividends Reinvested)
HIMS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HIMS five years ago would be worth $23,764 today (with dividends reinvested), compared to $817 for GDRX. Over the past 12 months, LFST leads with a +60.6% total return vs HIMS's -51.0%. The 3-year compound annual growth rate (CAGR) favors HIMS at 29.4% vs PGNY's -18.1% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -25.6% | -23.2% | +27.2% | +3.3% | +10.6% |
| 1-Year ReturnPast 12 months | -18.2% | -51.0% | +60.6% | -25.1% | +34.7% |
| 3-Year ReturnCumulative with dividends | -45.0% | +116.6% | +4.1% | -38.4% | +36.6% |
| 5-Year ReturnCumulative with dividends | -62.9% | +137.6% | -59.6% | -91.8% | +17.0% |
| 10-Year ReturnCumulative with dividends | +20.2% | +161.9% | -59.6% | -94.4% | +3.5% |
| CAGR (3Y)Annualised 3-year return | -18.1% | +29.4% | +1.4% | -14.9% | +11.0% |
Risk & Volatility
Evenly matched — LFST and CVS each lead in 1 of 2 comparable metrics.
Risk & Volatility
CVS is the less volatile stock with a 0.05 beta — it tends to amplify market swings less than HIMS's 2.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LFST currently trades 99.6% from its 52-week high vs HIMS's 36.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.71x | 2.40x | 1.20x | 1.58x | 0.05x |
| 52-Week HighHighest price in past year | $28.75 | $70.43 | $8.89 | $5.81 | $88.63 |
| 52-Week LowLowest price in past year | $16.10 | $13.74 | $3.74 | $1.77 | $58.35 |
| % of 52W HighCurrent price vs 52-week peak | +66.6% | +36.4% | +99.6% | +48.9% | +98.5% |
| RSI (14)Momentum oscillator 0–100 | 57.6 | 54.5 | 60.4 | 66.1 | 69.3 |
| Avg Volume (50D)Average daily shares traded | 1.5M | 34.9M | 2.9M | 2.3M | 7.4M |
Analyst Outlook
GDRX leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: PGNY as "Buy", HIMS as "Hold", LFST as "Buy", GDRX as "Hold", CVS as "Buy". Consensus price targets imply 60.8% upside for PGNY (target: $31) vs 5.1% for LFST (target: $9). CVS is the only dividend payer here at 3.06% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | $30.80 | $29.67 | $9.30 | $3.19 | $95.20 |
| # AnalystsCovering analysts | 20 | 19 | 11 | 24 | 41 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +3.1% |
| Dividend StreakConsecutive years of raises | — | — | — | 1 | 0 |
| Dividend / ShareAnnual DPS | — | — | — | — | $2.67 |
| Buyback YieldShare repurchases ÷ mkt cap | +5.2% | +1.4% | 0.0% | +21.3% | 0.0% |
GDRX leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). PGNY leads in 1 (Profitability & Efficiency). 1 tied.
PGNY vs HIMS vs LFST vs GDRX vs CVS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is PGNY or HIMS or LFST or GDRX or CVS a better buy right now?
For growth investors, Hims & Hers Health, Inc.
(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus 0. 6% for GoodRx Holdings, Inc. (GDRX). Progyny, Inc. (PGNY) offers the better valuation at 29. 5x trailing P/E (16. 4x forward), making it the more compelling value choice. Analysts rate Progyny, Inc. (PGNY) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — PGNY or HIMS or LFST or GDRX or CVS?
On trailing P/E, Progyny, Inc.
(PGNY) is the cheapest at 29. 5x versus LifeStance Health Group, Inc. at 442. 5x. On forward P/E, GoodRx Holdings, Inc. is actually cheaper at 9. 0x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — PGNY or HIMS or LFST or GDRX or CVS?
Over the past 5 years, Hims & Hers Health, Inc.
(HIMS) delivered a total return of +137. 6%, compared to -91. 8% for GoodRx Holdings, Inc. (GDRX). Over 10 years, the gap is even starker: HIMS returned +161. 9% versus GDRX's -94. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — PGNY or HIMS or LFST or GDRX or CVS?
By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.
05β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 4647% more volatile than CVS relative to the S&P 500. On balance sheet safety, Progyny, Inc. (PGNY) carries a lower debt/equity ratio of 5% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — PGNY or HIMS or LFST or GDRX or CVS?
By revenue growth (latest reported year), Hims & Hers Health, Inc.
(HIMS) is pulling ahead at 59. 0% versus 0. 6% for GoodRx Holdings, Inc. (GDRX). On earnings-per-share growth, the picture is similar: LifeStance Health Group, Inc. grew EPS 113. 3% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — PGNY or HIMS or LFST or GDRX or CVS?
Hims & Hers Health, Inc.
(HIMS) is the more profitable company, earning 5. 5% net margin versus 0. 4% for CVS Health Corporation — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GDRX leads at 13. 4% versus 1. 8% for LFST. At the gross margin level — before operating expenses — GDRX leads at 82. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is PGNY or HIMS or LFST or GDRX or CVS more undervalued right now?
On forward earnings alone, GoodRx Holdings, Inc.
(GDRX) trades at 9. 0x forward P/E versus 121. 1x for LifeStance Health Group, Inc. — 112. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PGNY: 60. 8% to $30. 80.
08Which pays a better dividend — PGNY or HIMS or LFST or GDRX or CVS?
In this comparison, CVS (3.
1% yield) pays a dividend. PGNY, HIMS, LFST, GDRX do not pay a meaningful dividend and should not be held primarily for income.
09Is PGNY or HIMS or LFST or GDRX or CVS better for a retirement portfolio?
For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
05), 3. 1% yield). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 40 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CVS: +3. 5%, HIMS: +161. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between PGNY and HIMS and LFST and GDRX and CVS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: PGNY is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock; LFST is a small-cap quality compounder stock; GDRX is a small-cap quality compounder stock; CVS is a mid-cap income-oriented stock. CVS pays a dividend while PGNY, HIMS, LFST, GDRX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.